Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

By | June 4, 2022
In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial’s prespecified level for statistical significance.